CNBC Africa

Newsfeed

BRIEF-Bergenbio Announces Stopped Recruitment To The Bemcentinib Arm In UK Accord Covid Platform Trial

PUBLISHED: Tue, 30 Mar 2021 20:09:19 GMT

March 30 (Reuters) – Bergenbio ASA:

* BERGENBIO ANNOUNCES STOPPED RECRUITMENT TO THE BEMCENTINIB ARM IN UK ACCORD COVID PLATFORM TRIAL

* NO SAFETY CONCERNS HAVE BEEN IDENTIFIED.

* DECISION HAS BEEN MADE TO HALT UK RECRUITMENT AT 30 PATIENTS, SIMILAR NUMBER OF MATCHED CONTROLS, ENABLING A PROMPT ANALYSIS OF RESULTS

* DATA FROM ACCORD STUDY AND BERGENBIO’S PHASE II COVID-19 TRIAL STUDY WILL BE ANALYSED SEPARATELY

* BERGENBIO ASA – DATA FROM ACCORD STUDY AND BERGENBIO’S PHASE II COVID-19 TRIAL STUDY WILL BE ANALYSED IN COMBINATION IN A META-ANALYSIS

* BERGENBIO- PHASE II TRIAL OF BEMCENTINIB FOR TREATMENT OF COVID-19 IN HOSPITALISED PATIENTS IN SOUTH AFRICA AND INDIA COMPLETED RECRUITMENT Source text for Eikon: Further company coverage:

(c) Copyright Thomson Reuters 2021. Click For Restrictions – https://agency.reuters.com/en/copyright.html